VK-2019: EBNA1 Inhibitor

VK-2019 is a potent, selective EBNA1 inhibitor. Preclinical studies have demonstrated that VK-2019 is capable of significantly reducing EBV levels in vitro and in vivo. In animal models, VK-2019 has demonstrated a significant reduction in both nasopharyngeal and B-cell malignancies.

VK-2019 has been studied in a Phase 1/2a clincal study in nasopharyngeal cancer patients. VK-2019 demonstrated excellent safety and tolerability and showed promising signs of efficacy (Colevas A 2023).  A clinical study in B-cell lymphoma patients is planned for 2025.